Where is Multiply Labs headquartered?

Multiply Labs is headquartered in San Francisco, United States. The company has a team of 51-100 people.

What does Multiply Labs do?

Multiply Labs operates in the AI in Biotech / Drug Discovery sector. Robotic biomanufacturing infrastructure company automating cell and gene therapy manufacturing using physical AI and robotics. Automates existing GMP-validated lab instruments inside a closed robotic cluster, increasing throughput up to 100x and decreasing costs by 74% without requiring process transfer to new equipment.

When was Multiply Labs founded?

Multiply Labs was founded in 2016. It is based in San Francisco, United States.

Who is the CEO of Multiply Labs?

Fred Parietti is the CEO of Multiply Labs. The company was founded in 2016.

Where is Multiply Labs located?

Multiply Labs is headquartered in San Francisco, United States.

What funding stage is Multiply Labs at?

Multiply Labs is currently at the Active stage.

How many employees does Multiply Labs have?

Multiply Labs has approximately 51-100 employees.

Multiply Labs

Category: AI in Biotech / Drug Discovery

Robotic biomanufacturing infrastructure company automating cell and gene therapy manufacturing using physical AI and robotics. Multiply Labs was founded in 2016. The company is led by Fred Parietti. Based in San Francisco, United States. Team size: 51-100. Total funding raised: $41.3M. Latest round: Venture Round. Key investors include Casdin Capital, Founders Fund, Lux Capital, Fifty Years, Garage Capital, Y Combinator, P101, Pegasus Tech Ventures, Graph Ventures.

Founded: 2016
Headquarters: San Francisco, United States
Team size: 51-100
Total funding: $41.3M

Value proposition

Automates existing GMP-validated lab instruments inside a closed robotic cluster, increasing throughput up to 100x and decreasing costs by 74% without requiring process transfer to new equipment.

Products and solutions

The Robotic Cluster (closed automated system integrating existing GMP instruments), unit-operation automation software, real-time sensor monitoring and 21 CFR Part 11 compliant electronic records/quality system integration.

Unique value

Physical AI-driven robotic automation of biologics manufacturing that adapts to a customer's existing validated instrument ecosystem rather than requiring new process validation.

Target customer

Pharmaceutical and biotech companies manufacturing advanced/personalized therapies (cell and gene therapy), including large pharma and clinical-stage biotechs.

Industries served

Biotech / Pharma manufacturing, Cell & Gene Therapy

Technology advantage

Uses NVIDIA Omniverse for digital twins of lab environments and NVIDIA Isaac Sim / GR00T for training robots via imitation learning and simulation; parallel orchestration across GMP instrument clusters; closed sterile robotic environment reducing contamination risk.

How they differentiate

Unlike single unit-operation automation vendors, Multiply Labs automates a customer's entire existing instrument ecosystem within one closed robotic system, avoiding process re-validation and enabling modular scale-out by deploying additional clusters.

Main competitors

Cellares, Ori Biotech, Cellular Origins

Key partnerships

NVIDIA (Isaac Sim / Omniverse / GR00T), Universal Robots, Thermo Fisher Scientific, AstraZeneca, Legend Biotech, Kyverna Therapeutics, Cytiva, Charles River Laboratories, Stanford LCGM, UCSF, CPC Biotech, GenScript

Notable customers

AstraZeneca, Legend Biotech, Kyverna Therapeutics, Thermo Fisher Scientific (technology partner)

Major milestones

2016: Founded (Y Combinator), 2021: $20M Series A led by Casdin Capital, 2023: $11.1M convertible note, 2024: Expanded Thermo Fisher partnership for cell expansion/separation automation, 2025-2026: Partnerships with AstraZeneca and Legend Biotech, NVIDIA Isaac/Omniverse/GR00T integration announced, Italian manufacturing subsidiary established, CEO Fred Parietti confirmed speaking at NVIDIA GTC 2026.

Growth metrics

Robotic cluster platform claims up to 100x throughput increase and 74% cost reduction versus manual biomanufacturing processes.

Market positioning

Positioned as a leading robotic biomanufacturing infrastructure platform alongside Cellares and Ori Biotech in the fast-growing cell & gene therapy automation market, differentiated by an 'automate your own instruments' approach.

Geographic focus

Primarily US-based with expansion into Europe (Italian manufacturing subsidiary announced 2026); competes globally in advanced therapy manufacturing automation.

Patents and IP

Multiply Labs Inc. has filed ~21 patents (CB Insights). Granted examples include US10456975B2 Multi-compartment capsule (issued Oct 29, 2019; inventors include Federico Parietti, Alice Melocchi) and Apparatus for facilitating automation of vessels (filed Jan 6, 2025; grant noted Mar 2026). Portfolio spans robotic vessel automation, flexure grippers, and capsule manufacturing.

About Fred Parietti

PhD in Mechanical Engineering from MIT; extensive experience in design and control of autonomous robotic systems prior to co-founding Multiply Labs.

Latest news about Multiply Labs

Multiply Labs is scaling robotics-driven biomanufacturing to industrialize cell therapy production. By integrating NVIDIA Physical AI and GR00T models, the company has reduced manufacturing costs by 7

More AI in Biotech / Drug Discovery companies

Official website: https://www.multiplylabs.com